JPMorgan analyst Chris Schott raised his price target for Bristol-Myers Squibb to $75 saying the company's opportunity in non-lung tumor types is broad and underappreciated. The analyst sees a number of $1B-plus indications for Opdivo beyond non-small-cell lung carcinoma, including kidney, liver, gastric, small cell lung and melanoma. These indications should represent the majority of Opdivo sales over time, Schott tells investors in a research note. The analyst keeps an Overweight rating on Bristol-Myers.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
Reports Q1 revenue $11.9B, consensus $11.46B. "We had a good start to 2024, with revenue growth, important advances in our pipeline and the closure of several strategically important transactions. Our focus remains on strengthening the company's long-term growth profile. As a part of our continued evolution, we're executing a strategic productivity initiative that will allow us to be more agile, drive efficiency across the company, and prioritize investing in opportunities where we see the greatest potential to get the most promising medicines to patients as quickly as possible," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "